Innovating to Transform Healthcare

At SYG BIOTECH, we develop cutting-edge solutions for the discovery and analysis of therapeutic proteins, enabling breakthroughs in oncology and beyond. In this post, we showcase our cost-effective in vitro PD-1 PD-L1 blockade assay that can be utilized to obtain quick, but essential potency in vitro data prior to progressing to in vivo animal pharmacology, toxicology and/or efficacy studies.

Target identification

Optimized for PD-1/PD-L1 Pathway Targeting: This assay is ideal for evaluating antibodies, Fc-fusion proteins, small molecule antagonists, and other biologics designed to inhibit the PD-1/PD-L1 interaction. It provides a robust and reliable platform for screening and characterizing therapeutic candidates with high sensitivity and specificity.

Learn more

Compound screening

Seamlessly integrate the PD-1/PD-L1 blockade assay into your lead compound screening program to accelerate the identification of promising therapeutic candidates in early drug discovery. Conduct high-throughput testing of novel compounds without the need for animal models, ensuring efficiency and ethical research practices.

LEARN MORE

Preclinical testing / Potency testing

Our PD-1/PD-L1 blockade assay precisely evaluates the potency of your antibody, enabling accurate EC50 value determination. In this assay, bioluminescence directly correlates with compound potency, providing a predictive basis for in vivo efficacy—crucial for informed therapeutic development.

LEARN MORE

Why choose us?

Assessing the interaction of a specific ligand with its target protein often involves expensive, time-consuming, and labor-intensive methods that require specialized equipment and expertise. In contrast, our method provides a cost-effective and user-friendly alternative to the traditional techniques. Protocols can be adapted to a wide range of research questions.

EASY-TO-USE

Our assay are easy to prepare, and familiar handling. Anyone can do it and get results in 3 simple steps

RAPID

The assay requires minimal preparation and provides results in hours (3 hours) instead of days compared to other identification methods.

Instrument free

Accessible to any standard biology lab.

COST-EFFECTIVE

Our method provides a cost-effective and user-friendly alternative to the traditional techniques

Precision

Adaptable to the specific detection of any protein and compatible with complex samples and suitable for small sample volumes.

Customisable

Protocols is highly flexible and can be tailored to measure various protein-protein interactions.

Discovering Precision Binders at Lightning Speed!

At SYG BIOTECH, we're pioneering the future of biotechnological solutions with a relentless commitment to enhancing health outcomes globally. Our latest innovation, a cutting-edge in vitro platform, is set to transform the landscape of therapeutic protein selection.
Our state-of-the-art platform accelerates the discovery and development of new therapeutic proteins, including VHHs, DARPINs, and other peptides. These proteins are engineered to precisely target immune checkpoints such as PD-1/PD-L1, pivotal in treating various diseases, especially in oncology by inhibiting these checkpoints. Our products can play a crucial role in cancer therapies, potentially turning the tide against this global challenge.
Alongside our therapeutic protein selection platform, we have developed an innovative rapid detection kit for PD-1 and PD-L1, as well as their inhibitors. This user-friendly kit enables researchers to detect and analyze these biomarkers with unprecedented speed and accuracy. Our technology not only facilitates the rapid development of personalized and effective therapies but also empowers the scientific community to push forward the boundaries of what's possible in medical science.

You would like to have access to this exciting technology?

Join us as we set new standards in biotechnology and unlock the potential of personalized medicine.

Get in touch